The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

START Trialists' Group, S M Bentzen, R K Agrawal, E G A Aird, J M Barrett, P J Barrett-Lee, J M Bliss, J Brown, J A Dewar, H J Dobbs, J S Haviland, P J Hoskin, P Hopwood, P A Lawton, B J Magee, J Mills, D A L Morgan, J R Owen, S Simmons, G Sumo, M A Sydenham, K Venables, J R Yarnold, W P Abram, J Clarke, J J A McAleer, J D Graham, P Riddle, S Goodman, M Tomlinson, K Benstead, R Counsell, S A G Elyan, J R Owen, B Lavery, E Sugden, J Dobbs, S Whittaker, C Brammer, M Churn, D J A Adamson, J A Dewar, D A L Morgan, J M Barrett, C D A Charlton, P Bliss, A Goodman, A Holmes, A Hong, A Neal, G Ross, A Rostom, D Tait, J R Yarnold, G Ross, M Illsley, R Laing, A Neal, C Topham, C Topham, S Whittaker, C Trask, P Bliss, A G Goodman, P J Barrett-Lee, T D L Crosby, C C Gaffney, T W O Tilsley, A Barrett, M Armitage, S M Bentzen, U Chetty, P Mayles, L Walker, H Lucraft, M Parmar, I Turesson, M Carling, J Pritchard, M King, E Parkin, K Law, S Perkins, U Wells, START Trialists' Group, S M Bentzen, R K Agrawal, E G A Aird, J M Barrett, P J Barrett-Lee, J M Bliss, J Brown, J A Dewar, H J Dobbs, J S Haviland, P J Hoskin, P Hopwood, P A Lawton, B J Magee, J Mills, D A L Morgan, J R Owen, S Simmons, G Sumo, M A Sydenham, K Venables, J R Yarnold, W P Abram, J Clarke, J J A McAleer, J D Graham, P Riddle, S Goodman, M Tomlinson, K Benstead, R Counsell, S A G Elyan, J R Owen, B Lavery, E Sugden, J Dobbs, S Whittaker, C Brammer, M Churn, D J A Adamson, J A Dewar, D A L Morgan, J M Barrett, C D A Charlton, P Bliss, A Goodman, A Holmes, A Hong, A Neal, G Ross, A Rostom, D Tait, J R Yarnold, G Ross, M Illsley, R Laing, A Neal, C Topham, C Topham, S Whittaker, C Trask, P Bliss, A G Goodman, P J Barrett-Lee, T D L Crosby, C C Gaffney, T W O Tilsley, A Barrett, M Armitage, S M Bentzen, U Chetty, P Mayles, L Walker, H Lucraft, M Parmar, I Turesson, M Carling, J Pritchard, M King, E Parkin, K Law, S Perkins, U Wells

Abstract

Background: The international standard radiotherapy schedule for breast cancer treatment delivers a high total dose in 25 small daily doses (fractions). However, a lower total dose delivered in fewer, larger fractions (hypofractionation) is hypothesised to be at least as safe and effective as the standard treatment. We tested two dose levels of a 13-fraction schedule against the standard regimen with the aim of measuring the sensitivity of normal and malignant tissues to fraction size.

Methods: Between 1998 and 2002, 2236 women with early breast cancer (pT1-3a pN0-1 M0) at 17 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2.0 Gy versus 41.6 Gy or 39 Gy in 13 fractions of 3.2 Gy or 3.0 Gy over 5 weeks. Women were eligible if they were aged over 18 years, did not have an immediate surgical reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specified principal endpoints were local-regional tumour relapse, defined as reappearance of cancer at irradiated sites, late normal tissue effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779.

Findings: 749 women were assigned to the 50 Gy group, 750 to the 41.6 Gy group, and 737 to the 39 Gy group. After a median follow up of 5.1 years (IQR 4.4-6.0) the rate of local-regional tumour relapse at 5 years was 3.6% (95% CI 2.2-5.1) after 50 Gy, 3.5% (95% CI 2.1-4.3) after 41.6 Gy, and 5.2% (95% CI 3.5-6.9) after 39 Gy. The estimated absolute differences in 5-year local-regional relapse rates compared with 50 Gy were 0.2% (95% CI -1.3% to 2.6%) after 41.6 Gy and 0.9% (95% CI -0.8% to 3.7%) after 39 Gy. Photographic and patient self-assessments suggested lower rates of late adverse effects after 39 Gy than with 50 Gy, with an HR for late change in breast appearance (photographic) of 0.69 (95% CI 0.52-0.91, p=0.01). From a planned meta-analysis with the pilot trial, the adjusted estimates of alpha/beta value for tumour control was 4.6 Gy (95% CI 1.1-8.1) and for late change in breast appearance (photographic) was 3.4 Gy (95% CI 2.3-4.5).

Interpretation: The data are consistent with the hypothesis that breast cancer and the dose-limiting normal tissues respond similarly to change in radiotherapy fraction size. 41.6 Gy in 13 fractions was similar to the control regimen of 50 Gy in 25 fractions in terms of local-regional tumour control and late normal tissue effects, a result consistent with the result of START Trial B. A lower total dose in a smaller number of fractions could offer similar rates of tumour control and normal tissue damage as the international standard fractionation schedule of 50 Gy in 25 fractions.

Figures

Figure 1
Figure 1
Trial profile for START Trial A *Only major treatment deviations listed. Minor deviations due to public holidays, machine service days, and machine breakdowns not included.
Figure 2
Figure 2
Kaplan-Meier plot (A) and Nelson-Aalen cumulative hazard plot (B) of local-regional tumour relapse in 2236 patients
Figure 3
Figure 3
Kaplan-Meier plot of mild/marked change in breast appearance (photographic) in 1055 patients with breast conserving surgery
Figure 4
Figure 4
Forest plot of late normal tissue effects assessed as moderate/marked by patients and mild/marked from photographs

References

    1. Clarke M, Collins R, Darby S, for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106.
    1. Overgaard M, Bentzen SM, Christensen JJ, Madsen EH. The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiother Oncol. 1987;9:1–11.
    1. Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) 2001;13:71–81.
    1. Bentzen SM, Saunders MI, Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol. 1999;53:219–226.
    1. Stuschke M, Thames HD. Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials. Radiother Oncol. 1999;51:113–121.
    1. Whelan T, MacKenzie R, Julian J. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–1150.
    1. Yarnold J, Ashton A, Bliss J. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17.
    1. Owen JR, Ashton A, Bliss JM. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467–471.
    1. The START Trialists' Group The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008 doi: 10.1016/S0140-6736(08)60348-7. published online March 19.
    1. Hopwood P, Haviland J, Mills J, Sumo G, Bliss JM. The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial) Breast. 2007;16:241–251.
    1. ICRU. Prescribing, recording and reporting photon beam therapy. Bethsada: Interantional Commission on Radiation Units and Measurements (ICRU), 1999: Report 62. Supplement to ICRU Report 50.
    1. Venables K, Winfield E, Deighton A, Aird E, Hoskin P. Breast radiotherapy phantom design for the START trial. START trial management group. Br J Radiol. 2000;73:1313–1316.
    1. Venables K, Winfield E, Deighton A, Aird E, Hoskin P. The START trial-measurements in semi-anatomical breast and chest wall phantoms. Phys Med Biol. 2001;46:1937–1948.
    1. Venables K, Winfield E, Deighton A, Aird E, Hoskin P. A survey of radiotherapy quality control practice in the United Kingdom for the START trial. Radiother Oncol. 2001;60:311–318.
    1. Venables K, Winfield EA, Aird EG, Hoskin PJ. Three-dimensional distribution of radiation within the breast: an intercomparison of departments participating in the START trial of breast radiotherapy fractionation. Int J Radiat Oncol Biol Phys. 2003;55:271–279.
    1. Venables K, Miles EA, Aird EG, Hoskin PJ. The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiother Oncol. 2004;71:303–310.
    1. Venables K, Miles EA, Hoskin PJ, Aird EG. Verification films: a study of the daily and weekly reproducibility of breast patient set-up in the START trial. Clin Oncol (R Coll Radiol) 2005;17:337–342.
    1. Venables K, Miles EA, Aird EG, Hoskin PJ. What is the optimum breast plan: a study based on the START trial plans. Br J Radiol. 2006;79:734–739.
    1. Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
    1. Sprangers MA, Groenvold M, Arraras JI. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756–2768.
    1. Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer. 2001;37:189–197.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.
    1. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492–1495.
    1. Cohen L. Radiotherapy in breast cancer I. The dose-time relationship theoretical considerations. Br J Radiol. 1952;25:636–642.
    1. Douglas BG, Castro JR. Novel fractionation schemes and high linear energy transfer. Prog Exp Tumor Res. 1984;28:152–165.
    1. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: What is it, really? Radiother Oncol. 2005;76:1–3.
    1. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol. 1990;19:219–235.
    1. Hurkmans CW, Cho BC, Damen E, Zijp L, Mijnheer BJ. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol. 2002;62:163–171.
    1. Bentzen SM. Steepness of the radiation dose-response curve for dose-per-fraction escalation keeping the number of fractions fixed. Acta Oncol. 2005;44:825–828.
    1. Bentzen SM. High-tech in radiation oncology: should there be a ceiling? Int J Radiat Oncol Biol Phys. 2004;58:320–330.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren